Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
N/A
1(20.0%)
5Total
Phase 1(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03056235Not ApplicableCompleted

A Study to Evaluate the Efficacy of ELAPR002f in Females and Males With Atrophic Acne Scars

Role: lead

NCT02510768Phase 1Completed

A Study to Evaluate the Efficacy of ELAPR in Women With Striae Distensae Alba

Role: lead

NCT01463657Phase 1Completed

Split-face Comparison Study to Assess ELAPR Compared to Juvéderm® for the Treatment of Nasolabial Folds

Role: lead

NCT01466413Phase 1Completed

Two Formulations of ELAPR Compared to Restylane® Vital Light Following Repeat Implants in the Upper Arm Dermis

Role: lead

NCT01467778Phase 1Completed

Safety Study of Three Formulations of the Dermal Implant ELAPR

Role: lead

All 5 trials loaded